Sequenom ( will provide quantitative gene-expression (QGE) services to the Immune Tolerance Network (ITN;, an international collaboration of researchers that conducts clinical research of new immune tolerance therapies. It targets islet, kidney, and liver transplantation, autoimmune diseases, allergy, and asthma.

“Our choice of Sequenom’s MassArray® QGE technology and services is based on testing that demonstrated a high level of accuracy and sensitivity for quantitative gene-expression evaluation,” says Vicki Seyfert-Margolis, Ph.D., executive director, assay tolerance group for ITN. “Sequenom’s services also meet the ITN’s assay requirements for reproducibility and quality assurance.”

Next articleUMMZ Periodical Cicada Page